Extranodal NK/T cell lymphoma (ENKTCL) is a group of highly aggressive non-Hodgkin lymphoma associated with epstein-barr virus infection. Asparaginase-based chemoradiotherapy regimens are not effective in advanced patients. In recent years, anti-programmed-death receptor 1 (PD-1)/programmed-death receptor ligand 1 (PD-L1) immunotherapy has developed rapidly, which can effectively improve the prognosis of ENKTCL patients. But some patients with ENKTCL still have low response rate. This article reviews the mechanisms of resistance to anti-PD1/PD-L1 therapy and other immune targets in ENKTCL recently to change the traditional treatment mode of ENKTCL through the combination of different targeted drugs.
CD99 gene encodes a transmembrane protein and participates in cell differentiation, adhesion, migration and protein transport. The expression of CD99 is generally low in most normal tissues and cells, and CD99 is differentially expressed in bone marrow and the surface of lymphatic hematopoietic cells. This article reviews the research progress of CD99 in hematological diseases, explores the role of CD99 in myeloid and lymphocytic leukemia, and the significance of CD99 as a therapeutic target for hematological malignancies.
目的:探讨具有滤泡辅助T细胞（TFH）表型的淋巴结外周T细胞淋巴瘤的临床特点、诊断及治疗。方法:回顾分析威海市立医院2021年10月收治的1例具有TFH表型的淋巴结外周T细胞淋巴瘤患者临床资料，并进行相关文献复习。结果:患者经淋巴结活组织检查病理诊断为具有TFH表型的淋巴结外周T细胞淋巴瘤，前期给予7个疗程CHOPE方案治疗，行PET-CT检查未获得完全缓解，后改为程序性死亡受体1（PD-1）抑制剂及西达本胺联合GEMOX方案治疗4个疗程，再次行PET-CT评效达完全缓解。继以西达本胺维持治疗，监测病情持续稳定。结论:具有TFH表型的淋巴结外周T细胞淋巴瘤患者采用PD-1抑制剂及西达本胺联合化疗可取得良好疗效。
As a rare and heterogeneous group of non-Hodgkin lymphomas, most of peripheral T-cell lymphomas (PTCL) are highly aggressive and usually do not respond well to chemotherapy. The research found that the disorder of canonical Wnt signaling pathway is involved in the pathogenesis of some subtypes of PTCL. Canonical Wnt signaling pathway plays an important role in the development and differentiation of T-lymphocytes and tumorigenesis. In recent years, exploring the relationship between canonical Wnt signaling pathway and the development of PTCL is expected to provide new ideas and targets for the treatment of PTCL.
目的:探讨异基因造血干细胞移植（allo-HSCT）后腺病毒脑炎的诊断、鉴别诊断、治疗及预后。方法:回顾性分析2020年11月湖北医药学院附属人民医院收治的1例allo-HSCT后继发腺病毒脑炎患者的临床资料，并结合文献复习。结果:患者，女性，49岁，诊断为T淋巴母细胞淋巴瘤。给予单倍体造血干细胞移植后出现不明原因的低热、精神症状。脑脊液病原微生物二代基因测序检查发现有腺病毒感染的证据，在排除其他相关疾病后诊断腺病毒脑炎。给予更昔洛韦和膦甲酸钠抗病毒、丙种球蛋白冲击治疗后效果差。结论:腺病毒脑炎是allo-HSCT后中枢神经系统的一种严重并发症，临床表现缺乏特异性，若患者allo-HSCT后出现发热伴精神症状，经抗感染治疗无效需考虑合并腺病毒脑炎可能。一旦怀疑腺病毒脑炎应尽早行脑脊液腺病毒聚合酶链反应或病原微生物二代测序等明确腺病毒感染的证据，并尽早使用西多福韦或Brincidofovir、腺病毒特异性的细胞毒性T淋巴细胞来改善患者的预后。
